 | Up a level |
Weber, M S R; Duran Ramirez, J J; Hentzien, M; Cavassini, M; Bernasconi, E; Hofmann, E; Furrer, H; Kovari, H; Stöckle, M; Schmid, P; Haerry, D; Braun, D L; Günthard, H F; Kusejko, K (2024). Time Trends in Causes of Death in People with HIV: Insights from the Swiss HIV Cohort Study. (In Press). Clinical infectious diseases Oxford University Press 10.1093/cid/ciae014
Roen, A O; Podlekareva, D; Miller, R F; Mocroft, A; Panteleev, A; Skrahina, A; Miro, J M; Cayla, J A; Tetradov, S; Derisova, E; Furrer, H; Losso, M H; Vassilenko, A; Girardi, E; Lundgren, J D; Post, F A; Kirk, O (2020). A new health care index predicts short term mortality for TB and HIV co-infected people. The international journal of tuberculosis and lung disease, 24(9), pp. 956-962. IUATLD 10.5588/ijtld.19.0568
Aebi-Popp, K; Wandeler, G; Salazar Vizcaya, L; Metzner, K; Stöckle, M; Cavassini, M; Hoffmann, M; Lüthi, A; Suter, F; Bernasconi, E; Fehr, J; Furrer, H; Rauch, A (2018). Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV medicine, 19(6), pp. 420-425. Blackwell Science 10.1111/hiv.12602
Braun, Julia; Held, Leonhard; Ledergerber, Bruno; Egger, M; Furrer, H; Keiser, O; Rauch, Andri; Schöni-Affolter, F; Swiss HIV Cohort Study, (2014). Accounting for baseline differences and measurement error in the analysis of change over time. Statistics in medicine, 33(1), pp. 2-16. Wiley-Blackwell 10.1002/sim.5910
Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B; Swiss HIV Cohort Study Group, (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV medicine, 13(2), pp. 118-26. Oxford: Blackwell Science 10.1111/j.1468-1293.2011.00949.x
Vrouenraets, S M E; Wit, F W N M; Garcia, E Fernandez; Huber, M; Brinkman, K; Moyle, G; Domingo, P; Tarr, P E; Podzamczer, D; Ristola, M; Gatell, J M; Livrozet, J M; Furrer, H; Reiss, P; PREPARE Study Group, (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV clinical trials, 13(2), pp. 103-10. St. Louis, Mo.: Thomas Land Publishers
Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R; Swiss HIV Cohort Study (SHCS), (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine, 12(5), pp. 279-88. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00880.x
El Amari, E Boffi; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, Hh; Bernasconi, E; Hirschel, B; Swiss HIV Cohort Study, (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV medicine, 12(7), pp. 394-402. Oxford: Blackwell Science 10.1111/j.1468-1293.2010.00900.x
Bucher, HC; Richter, W; Glass, TR; Magenta, L; Wang, Q; Cavassini, M; Vernazza, P; Hirschel, B; Weber, R; Furrer, H; Battegay, M; Bernasconi, E (2011). Small dense lipoproteins, apolipoprotein B and risk of coronary events in HIV-infected patients on antiretroviral therapy. Journal of acquired immune deficiency syndromes JAIDS, 60(2), pp. 135-142. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/QAI.0b013e31824476e1
Franceschi, S; Lise, M; Clifford, G M; Rickenbach, M; Levi, F; Maspoli, M; Bouchardy, C; Dehler, S; Jundt, G; Ess, S; Bordoni, A; Konzelmann, I; Frick, H; Dal Maso, L; Elzi, L; Furrer, H; Calmy, A; Cavassini, M; Ledergerber, B and Keiser, O (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British journal of cancer, 103(3), pp. 416-422. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6605756
Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV medicine, 10(7), pp. 407-16. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00701.x
Combescure, Christophe; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV medicine, 10(8), pp. 470-6. Oxford: Blackwell Science 10.1111/j.1468-1293.2009.00714.x
Gayet-Ageron, A; Ninet, B; Toutous-Trellu, L; Lautenschlager, S; Furrer, H; Piguet, V; Schrenzel, J; Hirschel, B (2009). Assessment of a real-time PCR test to diagnose syphilis from diverse biological samples. Sexually transmitted diseases, 85(4), pp. 264-9. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1136/sti.2008.034314
Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV medicine, 9(6), pp. 427-32. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00578.x
Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV medicine, 9(6), pp. 397-405. Oxford: Blackwell Science 10.1111/j.1468-1293.2008.00566.x
Elzi, L; Schlegel, M; Weber, R; Hirschel, B; Cavassini, M; Schmid, P; Bernasconi, E; Rickenbach, M; Furrer, H; Swiss, HIV Cohort Study (2007). Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clinical infectious diseases, 44(1), pp. 94-102. Cary, N.C.: The University of Chicago Press 10.1086/510080
Sterne, JA; May, M; Bucher, HC; Ledergerber, B; Furrer, H; Cavassini, M; Bernasconi, E; Hirschel, B; Egger, M; Swiss, HIV Cohort (2007). HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Journal of internal medicine, 261(3), pp. 255-67. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2796.2006.01761.x
Ledergerber, B; Furrer, H; Rickenbach, M; Lehmann, R; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Egger, M; Weber, R; Swiss, HIV Cohort Study (2007). Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical infectious diseases, 45(1), pp. 111-9. Cary, N.C.: The University of Chicago Press 10.1086/518619
Bergmann-Hug, K; Furrer, H; Helbling, A (2007). Attagenus pellio: a potential cause of indoor allergy. Journal of investigational allergology & clinical immunology, -17(3), pp. 203-4. Barcelona: Esmon Publicidad
Fux, CA; Simcock, M; Wolbers, M; Bucher, HC; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss, HIV Cohort Study (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8), pp. 1165-73. London: International Medical Press
Wolbers, M; Opravil, M; von Wyl, V; Hirschel, B; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M; Yerly, S; Günthard, H; Bucher, HC; Swiss, HIV Cohort Study (2007). Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS, 21(16), pp. 2201-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e3282efacb1
Simcock, M; Blasko, M; Karrer, U; Bertisch, B; Pless, M; Blumer, L; Vora, S; Robinson, JO; Bernasconi, E; Terziroli, B; Moirandat-Rytz, S; Furrer, H; Hirschel, B; Vernazza, P; Sendi, P; Rickenbach, M; Bucher, HC; Battegay, M; Koller, MT and Swiss, HIV Cohort Study (2007). Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy, 12(6), pp. 931-9. London: International Medical Press
Wolbers, M; Battegay, M; Hirschel, B; Furrer, H; Cavassini, M; Hasse, B; Vernazza, PL; Bernasconi, E; Kaufmann, G; Bucher, HC; Swiss, HIV Cohort Study (2007). CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy, 12(6), pp. 889-97. London: International Medical Press
von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, PL; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, HF; for, the Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine, 167(16), pp. 1782-90. Chicago, Ill.: American Medical Association 10.1001/archinte.167.16.1782
Arnedo, M; Taffé, P; Sahli, R; Furrer, H; Hirschel, B; Elzi, L; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Bergmann, S; Beckmann, JS; Telenti, A; Tarr, PE; Swiss, HIV Cohort Study (2007). Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and genomics, 17(9), pp. 755-64. London: Lippincott Williams & Wilkins 10.1097/FPC.0b013e32814db8b7
Glass, TR; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2007). Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV clinical trials, 8(2), pp. 77-85. St. Louis, Mo.: Thomas Land Publishers 10.1310/hct0802-77
Wunder, DM; Bersinger, NA; Fux, CA; Mueller, NJ; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H; HIV Cohort Study, Swiss (2007). Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antiviral therapy, 12(2), pp. 261-5. London: International Medical Press
Rauch, A; Laird, R; McKinnon, E; Telenti, A; Furrer, H; Weber, R; Smillie, D; Gaudieri, S; the, Swiss HIV Cohort Study (2007). Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue antigens, 69 Suppl 1, pp. 237-240. Oxford: Wiley-Blackwell 10.1111/j.1399-0039.2006.773_4.x
Rotger, M; Tegude, H; Colombo, S; Cavassini, M; Furrer, H; Décosterd, L; Blievernicht, J; Saussele, T; Günthard, H F; Schwab, M; Eichelbaum, M; Telenti, A; Zanger, U M (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clinical pharmacology & therapeutics, 81(4), pp. 557-66. New York, N.Y.: Nature Publishing Group 10.1038/sj.clpt.6100072
Müller, NJ; Furrer, H; Kaiser, L; Hirschel, B; Cavassini, M; Fellay, J; Chave, JP; Wüthrich, RP; Weber, M; Müllhaupt, B; Candinas, D; Reichen, J; Giostra, E; Mentha, G; Halkic, N; Hirsch, HH; Weber, R; Swiss, HIV Cohort Study (2006). HIV and solid organ transplantation: the Swiss experience. Swiss medical weekly, 136(11-12), pp. 194-6. Muttenz: EMH Schweizerischer Ärzteverlag
Colombo, S; Buclin, T; Décosterd, LA; Telenti, A; Furrer, H; Lee, BL; Biollaz, J; Eap, CB; Swiss, HIV Cohort Study (2006). Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology & therapeutics, 80(4), pp. 307-18. New York, N.Y.: Nature Publishing Group 10.1016/j.clpt.2006.06.006
Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC; Swiss, HIV Cohort Study (2006). Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine, 7(6), pp. 404-10. Oxford: Blackwell Science 10.1111/j.1468-1293.2006.00400.x
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Briel, M; Bucher, H C; Boscacci, R; Furrer, H (2006). Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane database of systematic reviews, 3(3), CD006150. Chichester: WileyInterscience 10.1002/14651858.CD006150
Colombo, S; Telenti, A; Buclin, T; Furrer, H; Lee, BL; Biollaz, J; Decosterd, LA; Swiss, HIV Cohort Study (2006). Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Therapeutic drug monitoring, 28(3), pp. 332-8. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.ftd.0000211807.74192.62
Bertschy, S; Opravil, M; Cavassini, M; Bernasconi, E; Schiffer, V; Schmid, P; Flepp, M; Chave, JP; Christen, A; Furrer, H; Swiss, HIV Cohort Study (2006). Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clinical microbiology and infection, 12(7), pp. 666-71. Oxford: Blackwell Publishing 10.1111/j.1469-0691.2006.01459.x
Zinkernagel, AS; von Wyl, V; Ledergerber, B; Rickenbach, M; Furrer, H; Battegay, M; Hirschel, B; Tarr, PE; Opravil, M; Bernasconi, E; Schmid, P; Weber, R; Swiss, HIV Cohort Study (2006). Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy, 11(2), pp. 131-42. London: International Medical Press
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Rossi, M; Zimmerli, W; Furrer, H; Zanetti, G; Mühlemann, K; Täuber, MG; Schweizerische, Gesellschaft für Infektiologie (2005). [Antibiotic prophylaxis for late blood-borne infections of joint prostheses]. Schweizerische Monatsschrift für Zahnmedizin, 115(6), pp. 571-9. Bern: Schweizerische Zahnärzte-Gesellschaft
Briel, M; Boscacci, R; Furrer, H; Bucher, HC (2005). Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC infectious diseases, 5(5), p. 101. London: BioMed Central 10.1186/1471-2334-5-101
Karrer, U; Ledergerber, B; Furrer, H; Elzi, L; Battegay, M; Cavassini, M; Gayet-Ageron, A; Hirschel, B; Schmid, P; Russotti, M; Weber, R; Speck, RF; Swiss, HIV Cohort Study (2005). Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS, 19(17), pp. 1987-94. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000194136.73876.9c
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Wunder, D; Bersinger, NA; Fux, C; Weber, R; Bernasconi, E; Cavassini, M; Bucher, HC; Schiffer, V; Schmid, P; Furrer, H; Swiss, HIV Cohort Study (2005). Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS, 19(16), pp. 1837-42. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000189852.21441.2a
Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531
Young, J; Weber, R; Rickenbach, M; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy, 10(5), pp. 585-91. London: International Medical Press
Colombo, S; Soranzo, N; Rotger, M; Sprenger, R; Bleiber, G; Furrer, H; Buclin, T; Goldstein, D; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and genomics, 15(9), pp. 599-608. London: Lippincott Williams & Wilkins 10.1097/01.fpc.0000172241.42546.d3
Rauch, A; Rickenbach, M; Weber, R; Hirschel, B; Tarr, PE; Bucher, HC; Vernazza, P; Bernasconi, E; Zinkernagel, AS; Evison, J; Furrer, H; Swiss, HIV Cohort Study (2005). Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases, 41(3), pp. 395-402. Cary, N.C.: The University of Chicago Press 10.1086/431486
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
Cavassini, ML; D'Acremont, V; Furrer, H; Genton, B; Tarr, PE (2005). Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. Expert opinion on pharmacotherapy, 6(6), pp. 891-913. London: Informa Healthcare 10.1517/14656566.6.891
Rotger, M; Colombo, S; Furrer, H; Bleiber, G; Buclin, T; Lee, BL; Keiser, O; Biollaz, J; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics, 15(1), pp. 1-5. London: Lippincott Williams & Wilkins
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
Young, J; Rickenbach, M; Weber, R; Furrer, H; Bernasconi, E; Hirschel, B; Tarr, PE; Vernazza, P; Battegay, M; Bucher, HC (2005). Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy, 10(1), pp. 73-81. London: International Medical Press
Rauch, A; Egger, M; Reichen, J; Furrer, H; Swiss, HIV Cohort Study (2005). Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. Journal of acquired immune deficiency syndromes JAIDS, 38(2), pp. 238-40. Philadelphia, Pa.: Lippincott Williams & Wilkins 10.1097/01.qai.0000148535.97081.72
Low, Nicola; B, Bertisch; Hauser, C; M, Kluschke; Kasraian, S; Egli-Gany, Dianne; Smid, J; M, Unemo; Endimiani, A; Donà, V; Furrer, H (2017). O12.5 Factors associated with antimicrobial resistant gonorrhoea infections in men who have sex with men: case-control study. Sexually transmitted infections, 93(Suppl 2), A28.2-A28. BMJ Publishing Group 10.1136/sextrans-2017-053264.70
